Product Information
– for professionals only –

Phenylalanin^{50} minis

In Short

- Phenylalanin^{50} minis are a Food for Special Medical Purposes (FSMP) for use in the dietary management of rare metabolic disorders, e.g. Tyrosinemia, Alkaptonuria or FARS2 Deficiency, when supplementation with L-Phenylalanine is indicated
- highly concentrated, pressed and coated L-Phenylalanine – in tablet form
- easy to swallow – easy application
- neutral in smell and taste
- 50 mg (0,3 mmol) L-Phenylalanine per tablet – 100 g tin at 500 tablets
- Cave: Phenylalanin^{50} minis must not be confused with XPhe minis

Product Profile

Phenylalanin^{50} minis are highly concentrated L-Phenylalanine in tablet form – pressed and coated.
Phenylalanin^{50} minis allow a tasteless intake of this L-amino acid.
Due to their dosage form they offer a convenient alternative, flexible and easy to take and simple to measure out.
Phenylalanin^{50} minis are not fortified with micronutrients.

Administration

Phenylalanin^{50} minis should always be taken with a sufficient quantity of liquid. They should be taken along with other food and supplementary to the regular protein supplement – if applicable.

Intake

The tablets should be swallowed unchewed as whole tablets. They should always be taken with a sufficient quantity of liquid. The tablets are not intended to be dissolved in water or other drinks prior to intake and they are not meant to dissolve in the mouth. We recommend to take the tablets in an upright position. The box must be closed tightly after use, also with the inner lid.
Note: The tablets are covered with a tasteless coating. This makes it easy to swallow them. However the layer is very thin. Thus, if the tablets were kept in the mouth for too long, this layer would dissolve and release the typical taste of an amino acid. This is why we recommend the administration above.

Function Phenylalanin^{50} minis are suitable for prevention or correction of disease related L-Phenylalanine deficiencies.

Indication Phenylalanin^{50} minis are used in the dietary management of e.g. Tyrosinemia, in order to avoid too low Phe levels caused by the low Phenylalanine and low Tyrosine diet. Decreased Phe levels can lead to e.g. impaired growth or neurocognitive deficits (e.g. in Tyrosinemia type I).
Cave: Phenylalanin^{50} minis are not to be confused with **XPhe minis**, because **XPhe minis** do not contain L-Phenylalanine and they are intended for use in the dietary management of PKU/HPA.

Dosage The daily dosage depends on age, body weight and individual medical condition and is, just as the right time for the daily intake, determined under medical supervision.
Phenylalanin^{50} minis can easily be combined with the products of the ZeroTP-system.

Important Notice Must only be used under medical supervision. Not for use as a sole source of nutrition. For enteral use only. Only for people with rare metabolic disorders, e.g. Tyrosinemia, Alkaptonuria or FARS2 Deficiency. Phenylalanin^{50} minis are not suitable for infants in the first year of life.

References:

- Daly et al. (2012) Diurnal variation of phenylalanine concentrations in tyrosinaemia type 1: should we be concerned?; Journal of Human Nutrition and Dietetics 25(2):111-6. doi: 10.1111/j.1365-277X.2011.01215.x. Epub 2011 Dec 15.
- de Laet et al. (2011) Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type I; Developmental Medicine & Child Neurology 53(10):962-4. doi: 10.1111/j.1469-8749.2011.04048.x. Epub 2011 Jul 11.
- de Laet et al. (2013) Recommendations for the management of tyrosinaemia type 1; Orphanet Journal of Rare Diseases (8):8. doi: 10.1186/1750-1172-8-8.
- Kok et al. (2021) Treatment of ARS deficiencies with specific amino acids; Genetics in Medicine 23(11):2202-2207. doi: 10.1038/s41436-021-01249-z. Epub 2021 Jun 30.
- Konolova et al. (2013) Mitochondrial aminoacyl-tRNA synthetases in human disease; Molecular Genetics and Metabolism 108(4):206-11. doi: 10.1016/j.ymgme.2013.01.010. Epub 2013 Jan 26.
- Oswald et al. (2023) Treatment of Mitochondrial Phenylalanyl-tRNa-Synthetase Deficiency (FARS2) with Oral Phenylalanine; Neuropediatrics 54(5):351-355. doi: 10.1055/a-2008-4230. Epub 2023 Jan 5.
- van et al. (2014) Single amino acid supplementation in aminoacidopathies: a systematic review. Orphanet journal of rare diseases 9:7. doi: 10.1186/1750-1172-9-7.
- van Vliet et al. (2015) Infants with Tyrosinemia Type 1: Should phenylalanine be supplemented? Journal of Inherited Metabolic Disease reports 2015:18:117-24. doi: 10.1007/8904_2014_358. Epub 2014 Sep 26.
- Wilson et al. (2000) Phenylalanine supplementation improves the phenylalanine profile in tyrosinaemia; Journal of Inherited Metabolic Disease 23(7):677-83. doi: 10.1023/a:1005666426079.

NUTRITION INFORMATION

Phenylalanin[50] minis		100 g	0,20 g (1 tablet)
Energy	kJ	1419	3
	kcal	336	0,7
Fat	g	1	<0,1
of which saturates	g	1	<0,1
Carbohydrate	g	53	0,1
of which sugars	g	3	<0,1
Fibre	g	17	0,03
Protein eqv.	g	21	0,04
of which L-Phenylalanine	g	25	0,05
	mmol		0,3
Salt	g	0	0

INGREDIENTS

Maltodextrin, L-phenylalanine, bulking agent: microcrystalline cellulose, anti-caking agent: calcium silicate & magnesium stearate & magnesium carbonate & calcium phosphate, glazing agents: E 464 & E 463.

Delivery Unit	tin 500 tablets = 100 g
Article Number	xx-001-31796
Delivery to	Pharmacies, clinics
Storage	Store in a cool, dry place.

metaX Institut fuer Diaetetik GmbH
Am Strassbach 5
61169 Friedberg/Germany

phone +49 (0) 8432 - 94 86 0
e-mail service@metax.org
web metax-shop.org · metax.org

24/05/15 d22/06/14